Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Aug;86(8):951-9.
doi: 10.1007/s00109-008-0366-7. Epub 2008 Jun 10.

Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita

Affiliations

Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita

Alina Sesarman et al. J Mol Med (Berl). 2008 Aug.

Abstract

Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering disease caused by autoantibodies against type VII collagen. The neonatal Fc receptor (FcRn) regulates immunoglobulin G (IgG) homeostasis and thus controls serum levels of antibodies. In this study, we investigated the effects of FcRn deficiency on the levels of autoantibodies against type VII collagen and blistering in EBA. For this purpose, rabbit IgG against murine type VII collagen was injected into FcRn-deficient and wild-type (n = 10 per group) mice. Enzyme-linked immunosorbent assay levels of serum IgG against type VII collagen were significantly lower in mutant compared with wild-type mice. Analysis of serum levels of specific autoantibodies induced in FcRn-deficient and wild-type mice (n = 10 per group) by immunization with type VII collagen showed significantly lower serum levels of IgG against type VII collagen in FcRn-deficient mice compared with wild-type animals. Importantly, the extent of blistering disease after injection of IgG against type VII collagen was significantly reduced in FcRn-deficient mice compared to wild-type controls. Our data demonstrate that FcRn maintains levels of pathogenic autoantibodies and thereby promotes tissue injury in experimental EBA. Therefore, modulation of FcRn function using inhibitors may reduce pathogenic IgG levels, offering therapeutic benefit in patients with antibody-mediated diseases.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Invest Dermatol. 2002 Apr;118(4):664-71 - PubMed
    1. J Cell Mol Med. 2007 May-Jun;11(3):462-81 - PubMed
    1. Arthritis Res Ther. 2006;8(6):223 - PubMed
    1. Exp Dermatol. 2007 Jun;16(6):520-31 - PubMed
    1. Annu Rev Immunol. 2000;18:739-66 - PubMed

Publication types

LinkOut - more resources